Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

By sjmartinez • April 9, 2024

Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00568-1. doi: 10.1016/j.jaad.2024.03.041. Epub ahead of print. PMID: 38588819.

Tags: alanine aminotransferase, aspartate aminotransferase, bimekizumab, Dermatology, enzyme, Hepatic, Liver, liver fibrosis, plaque psoriasis, psoriasis, Publications, safety, transaminase

Inhibition of pyruvate oxidation diminishes melanoma progression

Seyran B, Avila I, Galvan C, Robles G, Murphy C, Christofk H, Lowry WE. Inhibition of pyruvate oxidation diminishes melanoma progression. J Invest Dermatol. 2024[...]

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender VD, Castelo-Soccio L, Cotsarelis G, Craiglow BG, Desai[...]

Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of Secondary Pathologic Consultation

Zhang R, Yueh K, Anderson M, Bennett RG. Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of[...]